Essential Resources
Prescriber Information
Patient Information
From Our Sponsors
Racial Disparities in Use of Diabetes Technology Widen among Medicare Enrollees
While use of insulin pumps and CGM increased over a 3-year study period for all racial-ethnic groups, the inequities were significant between White adults and all others.
CGM-measured Glucose Variability Associated with Diabetes Micro- and Macrovascular Complications
Glycemic variability and low time in range were associated with retinopathy, nephropathy, neuropathy, and CVD in a cohort of more than 20 000 persons, most with T2D.
Blood Glucose Levels in T2D: 42 Factors that Make a Difference
These 42 factors that affect blood glucose are listed in categories including food, activity, and biological influences. Perfect information to share with your patients with T2D.
Real Time CGM Improves A1c, Time in Range in T2D Patients on Less Intensive Treatment
CGMs have revolutionized diabetes management for patients and healthcare providers alike. This slide show summarizes the most recent integration enhancements.
Current Advances in Continuous Glucose Monitoring Technology
Greatest improvements in A1c, %TIR, and other glycemic parameters were seen in patients treated with ≤1 medication, in another challenge to current payer restrictions.
Continuous Glucose Monitoring for Type 2 Diabetes in Primary Care: 2021 Research Review
Continuous glucose monitoring for type 2 diabetes patients is gaining exposure in the literature with positive evidence accumulating. Examples follow.
DIABETES: 2021 Clinical Focus Collection
From expert interviews on novel treatments and FDA approvals to tests of your clinical knowledge and guideline recall, Patient Care Online summarizes the progress made in diabetes management in 2021.
Cardiovascular Risk Found Greatest in Prediabetes A1c Range
For individuals with A1c of 6.4-6.5%, just below the threshold for diabetes, risk of MACE was higher than for any other subgroup with A1c values ranging from 5.8-6.8%.
Tom Martens, MD, Talks about the Vision for CGM as Part of Primary Care for Type 2 Diabetes
MOBILE study lead author Tom Martens, MD, talks about the inherent benefits of CGM for T2D patients on basal insulin treated in primary care and also the challenges to this vision of patient care.
CGM vs BGM in T2 Diabetes: MOBILE Study Findings with PI Thomas W. Martens, MD
MOBILE study lead author Thomas W. Martens, MD, discusses results of the study which was designed to capture CGM results in real-world primary care practice.
